Brian J Lipworth

List of Publications by Year
in descending order

566 papers	19,779 citations	11651 70 h-index	22832 112 g-index
571 all docs	571 docs citations	571 times ranked	12630 citing authors

#	Article	IF	Citations
1	Repeatability of impulse oscillometry in patients with severe asthma. European Respiratory Journal, 2022, 59, 2101679.	6.7	15
2	Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1497-1505.	3.8	30
3	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
4	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air^{Â®} realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
5	Mepolizumab response in severe chronic rhinosinusitis with nasal polyps is dissociated from blood eosinophil levels. Journal of Allergy and Clinical Immunology, 2022, 149, 1817.	2.9	2
6	Combining low frequency oscillometry and spirometry measurements in relation to asthma control and exacerbations in moderate to severe asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	8
7	Combined medical and surgical therapy for chronic rhinosinusitis with nasal polyposis. Lancet Respiratory Medicine,the, 2022, 10, e38.	10.7	0
8	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	1.6	2
9	Comparison of rhinitis treatments using <scp>MASK</scp>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
10	Pragmatic reappraisal of long-acting muscarinic antagonists at steps 4 and 5 for persistent adult asthma. Annals of Allergy, Asthma and Immunology, 2022, 129, 274-275.	1.0	1
11	Forced Vital Capacity and Low Frequency Reactance Area Measurements Are Associated with Asthma Control and Exacerbations. Lung, 2022, 200, 301-303.	3.3	14
12	Oscillometry bronchodilator response in adult moderate to severe eosinophilic asthma patients: A prospective cohort study. Clinical and Experimental Allergy, 2022, 52, 1118-1120.	2.9	7
13	Low-Grade B Cell Lymphoproliferative Disorder Masquerading as Chronic Rhinosinusitis. Sinusitis, 2021, 5, 1-4.	0.8	1
14	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
15	Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis. Journal of Allergy and Clinical Immunology, 2021, 147, 413.	2.9	6
16	Endâ€point selection to determine the airwayâ€systemic ratio of inhaled corticosteroids in asthma. British Journal of Clinical Pharmacology, 2021, 87, 2401-2402.	2.4	2
17	Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents. European Respiratory Journal, 2021, 58, 2004107.	6.7	8
18	Real-life small airway outcomes in severe asthma patients receiving biologic therapies. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2907-2909.	3.8	15

#	Article	IF	Citations
19	Type 2 Asthma Inflammation and COVID-19: A Double Edged Sword. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1163-1165.	3.8	8
20	Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD. Journal of Allergy and Clinical Immunology, 2021, 147, 1117.	2.9	3
21	Normal spirometry equates to normal impulse oscillometry in healthy subjects. Respiratory Research, 2021, 22, 96.	3.6	0
22	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
23	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAACIâ€GA²LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
24	Inhaled triple therapy and airway hyperresponsiveness in persistent asthma. Annals of Allergy, Asthma and Immunology, 2021, 126, 597-598.	1.0	1
25	Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma. Annals of Allergy, Asthma and Immunology, 2021, 127, 548-552.	1.0	17
26	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3997-4004.	3.8	74
27	The Choice of Biologics in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4235-4238.	3.8	18
28	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respiratory Medicine,the, 2021, 9, 1467-1478.	10.7	84
29	Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3431-3439.e4.	3.8	6
30	Corticosteroid Protection Against COVID-19: Begin with the Nose. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3941-3943.	3.8	5
31	Considerations of a real life pragmatic clinical trial in adolescent asthma. European Respiratory Journal, 2021, 58, 2100461.	6.7	0
32	Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy. Lancet Respiratory Medicine,the, 2021, , .	10.7	1
33	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e97-e109.	5.6	69
34	High-dose budesonide for early COVID-19. Lancet, The, 2021, 398, 2147.	13.7	3
35	Airwave oscillometry and patient-reported outcomes in persistent asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 289-290.	1.0	7
36	Anti-inflammatory reliever therapy for asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 13-15.	1.0	11

#	Article	IF	Citations
37	Donâ€™t Forget about Facilitatory Effects of Corticosteroids on Î²2-Adrenoceptors in Acute Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1743-1743.	5.6	0
38	Systemic IL-6 and Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1324-1325.	5.6	11
39	Dupilumab for nasal polyposis. Lancet, The, 2020, 396, 233.	13.7	0
40	Predicting Severe Outcomes in COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2582-2584.	3.8	11
41	Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3363-3370.	3.8	32
42	Inhaled Corticosteroids and COVID-19. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 899-900.	5.6	13
43	Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. Clinical and Experimental Allergy, 2020, 50, 1140-1147.	2.9	16
44	2020 Updated Asthma Guidelines: Clinical utility of fractional exhaled nitric oxide (Feno) in asthma management. Journal of Allergy and Clinical Immunology, 2020, 146, 1281-1282.	2.9	13
45	Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis. Journal of Allergy and Clinical Immunology, 2020, 146, 683.	2.9	4
46	Impulse oscillometry bronchodilator response and asthma control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3610-3612.	3.8	11
47	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet, The, 2020, 396, e53.	13.7	27
48	Diagnosing adrenal insufficiency using ACTH stimulation test. European Respiratory Journal, 2020, 56, 2001478.	6.7	0
49	Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease . International Journal of COPD, 2020, Volume 15, 2015-2024.	2.3	3
50	Systemic effects of fluticasone on blood eosinophils in bronchiectasis. European Respiratory Journal, 2020, 56, 2002005.	6.7	1
51	Criteria for Airway Oscillometry Reversibility in Asthma. Chest, 2020, 158, 1282-1283.	0.8	3
52	Tocilizumab for severe COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e660.	3.9	4
53	COVID-19: Start with the nose. Journal of Allergy and Clinical Immunology, 2020, 146, 1214.	2.9	9
54	Pneumonia Due to Inhaled Corticosteroids in COPD. Chest, 2020, 157, 1683-1684.	0.8	0

#	Article	IF	Citations
55	Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 2020, 146, 128-136.e4.	2.9	783
56	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research, 2020, 21, 128.	3.6	4
57	Making simple things complicated using anti-inflammatory reliever therapy. European Respiratory Journal, 2020, 55, 2000267.	6.7	1
58	Systemic potency of fluticasone in asthma. European Respiratory Journal, 2020, 55, 2000104.	6.7	1
59	Allergic burden and response to dupilumab. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 822.	3.8	2
60	Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naÃ¯ve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. Respiratory Research, 2020, 21, 69.	3.6	9
61	Emerging Pharmacotherapy for Covid-19. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 133-137.	0.6	3
62	Use of inhaled corticosteroids in asthma and coronavirus disease 2019. Annals of Allergy, Asthma and Immunology, 2020, 125, 503-504.	1.0	8
63	Optimal asthma control in African American children with asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2121.	3.8	1
64	Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1714-1716.	3.8	28
65	How bad is the SAD phenotype in relation to asthma control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 427.	3.8	0
66	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies . International Journal of COPD, 2020, Volume 15, 99-106.	2.3	3
67	Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers. Chest, 2020, 157, 1045.	0.8	1
68	Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1798-1801.	3.8	40
69	Relative lung dose from antistatic valved holding chambers. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1166.	3.8	1
70	Effect of controller prescribing according to rs1042713 genotype on asthma related quality of life in young people (PACT): a randomized controlled trial. , 2020, , .		1
71	Real-World Studies in Infrequently Exacerbating Patients With COPD. Chest, 2019, 156, 415-416.	0.8	0
72	Bronchoprotective tolerance with inhaled corticosteroid/long-acting Î²-agonist treatment. Journal of Allergy and Clinical Immunology, 2019, 144, 873.	2.9	2

#	Article	IF	Citations
73	I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements. Lung, 2019, 197, 473-481.	3.3	21
74	Scottish consensus statement on the role of FeNO in adult asthma. Respiratory Medicine, 2019, 155, 54-57.	2.9	34
75	Resistance Heterogeneity and Small Airway Asthma Phenotype. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1441-1442.	5.6	0
76	Pragmatic evaluation of inhaled corticosteroid particle size formulations on asthma control. Clinical and Experimental Allergy, 2019, 49, 1321-1327.	2.9	2
77	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
78	Benefit:Risk Profile of Budesonide in Obstructive Airways Disease. Drugs, 2019, 79, 1757-1775.	10.9	24
79	Non-canonical Î²2-receptor signaling. Journal of Allergy and Clinical Immunology, 2019, 144, 1735.	2.9	1
80	Single Triple vs Dual InhalerÂTherapy. Chest, 2019, 155, 1078-1079.	0.8	1
81	Differences in asthma control and lung function in relation to allergic status. European Respiratory Journal, 2019, 53, 1802102.	6.7	0
82	Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD. European Respiratory Journal, 2019, 53, 1802420.	6.7	1
83	Does unified allergic airway disease impact on lung function and type 2 biomarkers?. Allergy, Asthma and Clinical Immunology, 2019, 15, 75.	2.0	6
84	Comparison of the effect of beclometasone/formoterol in asthma patients after methacholineâ€induced bronchoconstriction: A noninferiority study using metered dose vs . dry powder inhaler. British Journal of Clinical Pharmacology, 2019, 85, 729-736.	2.4	6
85	Effects of contrast administration on cardiac MRI volumetric, flow and pulse wave velocity quantification using manual and software-based analysis. British Journal of Radiology, 2018, 91, 20170717.	2.2	8
86	Pulmonary arterial stiffening in COPD and its implications for right ventricular remodelling. European Radiology, 2018, 28, 3464-3472.	4.5	13
87	Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD. Lung, 2018, 196, 15-18.	3.3	4
88	Asthma Step-Down Strategies: Perhaps the Patient Should Decide?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 644-645.	3.8	1
89	Does the asthma visual analog scale relate to the Asthma Control Questionnaire?. Annals of Allergy, Asthma and Immunology, 2018, 120, 533-535.	1.0	1
90	Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. Lung, 2018, 196, 11-14.	3.3	1

#	Article	IF	Citations
91	Blood eosinophils: The forgotten man of inhaled steroid dose titration. Clinical and Experimental Allergy, 2018, 48, 93-95.	2.9	17
92	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: AÂrandomized controlled study. Journal of Allergy and Clinical Immunology, 2018, 141, 1220-1230.	2.9	40
93	Current appraisal of single inhaler triple therapy in COPD. International Journal of COPD, 2018, Volume 13, 3003-3009.	2.3	25
94	Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. International Journal of COPD, 2018, Volume 13, 2969-2984.	2.3	34
95	Inhaled triple therapy in chronic obstructive pulmonary disease. Lancet, The, 2018, 392, 1112-1113.	13.7	0
96	What can we learn about COPD from impulse oscillometry?. Respiratory Medicine, 2018, 139, 106-109.	2.9	44
97	Anti-interleukin 13 for asthma: stick or twist?. Lancet Respiratory Medicine,the, 2018, 6, e46-e47.	10.7	9
98	Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of COPD, 2018, Volume 13, 1755-1765.	2.3	7
99	Is small airways dysfunction related to asthma control and type 2 inflammation?. Annals of Allergy, Asthma and Immunology, 2018, 121, 631-632.	1.0	23
100	Adrenal suppression with inhaled corticosteroids: the seed and the soil. Lancet Respiratory Medicine,the, 2018, 6, e19.	10.7	2
101	Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction. Journal of Allergy and Clinical Immunology, 2017, 139, 2013-2014.e1.	2.9	35
102	Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine, 2017, 15, 18.	5.5	67
103	Inhaled corticosteroid dose response in asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 179-185.	1.0	9
104	Debate on long-acting Î² agonists for asthma: they think it's all over. Lancet Respiratory Medicine,the, 2017, 5, e14-e15.	10.7	2
105	The case for impulse oscillometry in the management of asthma in children and adults. Annals of Allergy, Asthma and Immunology, 2017, 118, 664-671.	1.0	99
106	FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1082-1082.	5.6	2
107	An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. Npj Primary Care Respiratory Medicine, 2017, 27, 3.	2.6	16
108	Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 785-792.	0.5	10

#	Article	IF	Citations
109	Impact of Spacers on Therapeutic Ratio with Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1163.	3.8	1
110	Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma. Clinical and Experimental Allergy, 2017, 47, 1239-1245.	2.9	8
111	Drugâ€“device interaction for systemic effects of fluticasone in patients with asthma. Annals of Allergy, Asthma and Immunology, 2017, 119, 194.	1.0	1
112	Un-diagnosing persistent adult asthma. European Respiratory Journal, 2017, 50, 1701433.	6.7	8
113	Reappraisal of the clinical effect of mepolizumab. Lancet Respiratory Medicine,the, 2017, 5, e20.	10.7	0
114	A pragmatic approach to simplify inhaler therapy for COPD. Lancet Respiratory Medicine,the, 2017, 5, 679-681.	10.7	6
115	The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. International Journal of COPD, 2016, Volume 11, 2851-2858.	2.3	4
116	Letter to the editor: Comparing pace and speed in the pulmonary circulation?. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H949-H949.	3.2	1
117	Respiratory effect of betaâ€blocker eye drops in asthma: populationâ€based study and metaâ€analysis of clinical trials. British Journal of Clinical Pharmacology, 2016, 82, 814-822.	2.4	42
118	Effects of the inverse alphaâ€agonist doxazosin in allergic rhinitis. Clinical and Experimental Allergy, 2016, 46, 696-704.	2.9	4
119	Beta-blockers in COPD: time for reappraisal. European Respiratory Journal, 2016, 48, 880-888.	6.7	60
120	Underuse of Î²-blockers in heart failure and chronic obstructive pulmonary disease. Heart, 2016, 102, 1909-1914.	2.9	65
121	IMPLICATION OF ALTERNATIVE MINIMAL CLINICALLY IMPORTANT DIFFERENCE THRESHOLD ESTIMATION METHODS ON TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2016, 32, 371-375.	0.5	3
122	Improvements with sublingual house dust mite immunotherapy in allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 634-635.	2.9	1
123	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
124	From mouse to man: predicting biased effects of betaâ€blockers in asthma. British Journal of Pharmacology, 2016, 173, 248-249.	5.4	3
125	Real-life effect of long-acting Î²2-agonist withdrawal in patients with controlled step 3 asthma. Annals of Allergy, Asthma and Immunology, 2016, 117, 430-431.	1.0	6
126	Assessment of proximal pulmonary arterial stiffness using magnetic resonance imaging: effects of technique, age and exercise. BMJ Open Respiratory Research, 2016, 3, e000149.	3.0	6

#	Article	IF	Citations
127	Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. Lung, 2016, 194, 259-266.	3.3	7
128	Inhaled corticosteroid dose-response on blood eosinophils in asthma. Lancet Respiratory Medicine,the, 2016, 4, e1.	10.7	3
129	Utility of impulse oscillometry in patients with moderate to severe persistent asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 601-603.	2.9	27
130	Is Gly16Arg Î²2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?. Lung, 2016, 194, 267-271.	3.3	3
131	Of mice and menâ€"the curious tale of Î² blockers in asthma. Lancet Respiratory Medicine,the, 2016, 4, 89-91.	10.7	1
132	Childhood asthma exacerbations and the Arg16 Î²2-receptor polymorphism: AÂmeta-analysis stratified by treatment. Journal of Allergy and Clinical Immunology, 2016, 138, 107-113.e5.	2.9	80
133	Inhaled treatment for chronic obstructive pulmonary disease: whatâ€™s new and how does it fit?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 505-512.	0.5	11
134	Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma. Journal of Allergy and Clinical Immunology, 2016, 137, 727-733.e1.	2.9	15
135	Clinical relevance of house dust mite immunotherapy. Journal of Allergy and Clinical Immunology, 2015, 135, 288.	2.9	1
136	Tiotropium in asthma. Lancet Respiratory Medicine,the, 2015, 3, e16-e17.	10.7	0
137	Biomarkers to predict inhaled corticosteroid response. Journal of Allergy and Clinical Immunology, 2015, 136, 515.	2.9	2
138	Triple inhaler therapy for COPD. Thorax, 2015, 70, 991-991.	5.6	1
139	Usefulness of impulse oscillometry for the assessment of airway hyperresponsiveness in mild-to-moderate adult asthma. Annals of Allergy, Asthma and Immunology, 2015, 115, 17-20.	1.0	24
140	<scp>NSAID</scp>â€exacerbated respiratory disease: a metaâ€analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 828-835.	5.7	62
141	Assessment of Spirometry and Impulse Oscillometry in Relation to Asthma Control. Lung, 2015, 193, 47-51.	3.3	38
142	Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. Lung, 2015, 193, 487-495.	3.3	7
143	The role of pulmonary arterial stiffness in COPD. Respiratory Medicine, 2015, 109, 1381-1390.	2.9	46
144	Nasal endoscopy to characterize sinonasal disease. Journal of Allergy and Clinical Immunology, 2015, 136, 212.	2.9	1

#	Article	IF	Citations
145	Î²2-Adrenergic receptor Gly16Arg polymorphism and impaired asthma control in corticosteroid-treated asthmatic adults. Annals of Allergy, Asthma and Immunology, 2015, 114, 421-423.	1.0	3
146	Lack of clinically relevant differences between combination therapy and monotherapy in COPD. European Respiratory Journal, 2014, 43, 1204-1204.	6.7	0
147	The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma. Clinical Science, 2014, 127, 635-643.	4.3	15
148	Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients. Clinical Science, 2014, 126, 75-83.	4.3	3
149	Effects of intravenous and oral Î²-blockade in persistent asthmatics controlled on inhaled corticosteroids. Heart, 2014, 100, 219-223.	2.9	18
150	Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology, 2014, 77, 55-62.	2.4	34
151	The potential role of direct and indirect bronchial challenge testing to identify overtreatment of community managed asthma. Clinical and Experimental Allergy, 2014, 44, 1240-1245.	2.9	17
152	Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. Journal of Allergy and Clinical Immunology, 2014, 134, 40-45.e10.	2.9	64
153	Small airway dysfunction is associated with poorer asthma control. European Respiratory Journal, 2014, 44, 1353-1355.	6.7	61
154	Impact of Long-Acting Bronchodilators and Exposure to Inhaled Corticosteroids on Mortality in COPD: A Real-Life Retrospective Cohort Study. Lung, 2014, 192, 649-652.	3.3	14
155	Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 293-300.	10.7	94
156	Influence of Î²2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma. Annals of Allergy, Asthma and Immunology, 2014, 112, 475-476.	1.0	4
157	Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respiratory Medicine,the, 2014, 2, 497-506.	10.7	140
158	Adrenal Suppression With Mometasone Furoate/Formoterol. Chest, 2014, 145, 1175-1176.	0.8	0
159	Adverse Respiratory Effect of Acute Î²-Blocker Exposure in Asthma. Chest, 2014, 145, 779-786.	0.8	88
160	Adverse Effects of Long-Acting Beta-Agonists on Airway Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 501-502.	2.9	1
161	Targeting the small airways asthma phenotype: if we can reach it, should we treatÂit?. Annals of Allergy, Asthma and Immunology, 2013, 110, 233-239.	1.0	37
162	Uncorrected nitric oxide levels in mild asthmatics produce flawed interpretation. Journal of Allergy and Clinical Immunology, 2013, 132, 1255.	2.9	1

#	Article	IF	Citations
163	Influence of Î²2-adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients. Annals of Allergy, Asthma and Immunology, 2013, 110, 161-164.	1.0	4
164	Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of addâ€on therapy. British Journal of Clinical Pharmacology, 2013, 75, 93-102.	2.4	15
165	Adrenal suppression with fluticasone furoate. Annals of Allergy, Asthma and Immunology, 2013, 110, 213.	1.0	0
166	Relationship of large and small airway response with inhaled corticosteroid to asthma control. Annals of Allergy, Asthma and Immunology, 2013, 111, 140-142.	1.0	1
167	Randomized Placebo-controlled Trial to Evaluate Chronic Dosing Effects of Propranolol in Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1308-1314.	5.6	50
168	Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clinical Science, 2013, 124, 521-528.	4.3	74
169	Explaining differential effects of tiotropium on mortality in COPD. Thorax, 2013, 68, 589-590.	5.6	4
170	Î²-Adrenoceptor Genotype and Bronchoprotective Subsensitivity with Long-Acting Î²-Agonists in Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1386-1387.	5.6	8
171	Systemic safety of fluticasone furoate/vilanterol combination. Thorax, 2013, 68, 1165.1-1165.	5.6	2
172	Left Ventricular Hypertrophy in COPD Without Hypoxemia. Chest, 2013, 143, 91-97.	0.8	26
173	Prospective Follow-Up of Novel Markers of Bone Turnover in Persistent Asthmatics Exposed to Low and High Doses of Inhaled Ciclesonide over 12 Months. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1929-1936.	3.6	12
174	Tiotropium in Asthma. New England Journal of Medicine, 2012, 367, 2552-2553.	27.0	5
175	The Impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-Acting Î²-Agonist Therapy in COPD. Chest, 2012, 141, 81-86.	0.8	88
176	Inhaled Corticosteroid Dose Response Using Domiciliary Exhaled Nitric Oxide in Persistent Asthma. Chest, 2012, 142, 1553-1561.	0.8	57
177	Fluticasone/Salmeterol Combination Confers Benefits in People With Asthma Who Smoke. Chest, 2012, 141, 330-338.	0.8	43
178	A Randomized Primary Care Trial of Steroid Titration Against Mannitol in Persistent Asthma. Chest, 2012, 141, 607-615.	0.8	56
179	Relationship of Mannitol Challenge to Methacholine Challenge and Inflammatory Markers in Persistent Asthmatics Receiving Inhaled Corticosteroids. Lung, 2012, 190, 513-521.	3.3	17
180	Are we overlooking persistent small airways dysfunction in community-managed asthma?. Annals of Allergy, Asthma and Immunology, 2012, 109, 185-189.e2.	1.0	71

#	Article	IF	Citations
181	Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline. Annals of Allergy, Asthma and Immunology, 2012, 108, 77-80.	1.0	5
182	Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2012, 108, 54-59.	1.0	2
183	Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma. Annals of Allergy, Asthma and Immunology, 2012, 109, 412-415.	1.0	37
184	Cardiac beta-2 adrenoceptor responses to formoterol and associated corticosteroid interactions. Annals of Allergy, Asthma and Immunology, 2012, 108, 68.	1.0	0
185	Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma?. Annals of Allergy, Asthma and Immunology, 2012, 108, 237-242.	1.0	55
186	Relationships between impulse oscillometry, spirometry and dyspnoea in COPD. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 111-115.	0.6	21
187	Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD. Lung, 2012, 190, 395-401.	3.3	8
188	Effects of hydrocortisone on acute Î²â€adrenoceptor blocker and histamine induced bronchoconstriction. British Journal of Clinical Pharmacology, 2012, 73, 717-726.	2.4	9
189	Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry. Annals of Allergy, Asthma and Immunology, 2011, 107, 317-322.	1.0	54
190	Nasal AMP and histamine challenge within and outside theÂpollen season in patients with seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 2011, 127, 173-178.e3.	2.9	8
191	Prescribing of Â-adrenoceptor antagonists in asthma: an observational study. Thorax, 2011, 66, 502-507.	5.6	15
192	Supervised step-down of inhaled corticosteroids in the community â€“ An observational study. Respiratory Medicine, 2011, 105, 558-565.	2.9	21
193	Treatment of Chronic Rhinosinusitis With Nasal Polyposis With Oral Steroids Followed by Topical Steroids. Annals of Internal Medicine, 2011, 154, 293.	3.9	150
194	Combined Oral and Intranasal Corticosteroid Therapy for Nasal Polyps. Annals of Internal Medicine, 2011, 155, 277.	3.9	8
195	Review: Tiotropium mist inhaler increases mortality in chronic obstructive pulmonary disease. Annals of Internal Medicine, 2011, 155, JC4.	3.9	0
196	Proof of concept study to evaluate stepâ€down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma. British Journal of Clinical Pharmacology, 2011, 71, 128-131.	2.4	5
197	Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide. British Journal of Clinical Pharmacology, 2011, 71, 504-513.	2.4	25
198	Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone and salmeterol: a reply. British Journal of Clinical Pharmacology, 2011, 72, 355-356.	2.4	0

#	Article	IF	Citations
199	Guidelines to establish relative potency are not in touch with reality. British Journal of Clinical Pharmacology, 2011, 72, 834-835.	2.4	1
200	Airway dysfunction in nasal polyposis: a spectrum of asthmatic disease?. Clinical and Experimental Allergy, 2011, 41, 1379-1385.	2.9	31
201	Assessment of Small-Airways Disease Using Alveolar Nitric Oxide and Impulse Oscillometry in Asthma and COPD. Lung, 2011, 189, 121-129.	3.3	90
202	Relationships Between Airway Hyperresponsiveness, Inflammation, and Calibre in Asthma. Lung, 2011, 189, 493-497.	3.3	8
203	Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. European Journal of Clinical Pharmacology, 2011, 67, 355-363.	1.9	13
204	Comparison of Montelukast Versus Salmeterol as Add-On to Inhaled Fluticasone in at-Risk Asthmatic Children Possessing the Homozygous Arginine-16 B2-Adrenoceptor Genotype- a Randomized Controlled Trial. Pediatric Research, 2011, 70, 17-17.	2.3	0
205	Effect of Â blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ, The, 2011, 342, d2549-d2549.	6.0	234
206	Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. European Respiratory Journal, 2011, 37, 206-209.	6.7	13
207	P257 Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Thorax, 2011, 66, A172-A172.	5.6	0
208	Paradoxical Trough Effects of Triple Therapy With Budesonide/Formoterol and Tiotropium Bromide on Pulmonary Function Outcomes in COPD. Chest, 2010, 138, 595-604.	0.8	16
209	Think the impossible: Î²-blockers for treating asthma. Clinical Science, 2010, 118, 115-120.	4.3	16
210	Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. British Journal of Clinical Pharmacology, 2010, 69, 637-644.	2.4	14
211	The minimal clinically important difference in allergic rhinitis. Clinical and Experimental Allergy, 2010, 40, 242-250.	2.9	83
212	Disconnect between standardized fieldâ€based testing and mannitol challenge in Scottish elite swimmers. Clinical and Experimental Allergy, 2010, 40, 731-737.	2.9	19
213	Effects of chlorine and exercise on the unified airway in adolescent elite Scottish swimmers. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 269-273.	5.7	27
214	Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 359-367.	5.7	35
215	Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 19-24.	5.6	76
216	Response to salbutamol in patients with mild asthma treated with nadolol. European Respiratory Journal, 2010, 36, 963-965.	6.7	35

#	Article	IF	Citations
217	P181 Better asthma control with montelukast than salmeterol in Arg-16 homozygous children with asthma. Thorax, 2010, 65, A154-A154.	5.6	2
218	Effect of systemic steroids on humming nasal nitric oxide in chronic rhinosinusitis with nasal polyposis. Annals of Allergy, Asthma and Immunology, 2010, 105, 412-417.	1.0	22
219	Relationship between fractional exhaled nitric oxide and nasal nitric oxide in airways disease. Annals of Allergy, Asthma and Immunology, 2010, 105, 162-167.	1.0	34
220	Inflammation, glucocorticoids and risk of cardiovascular disease. Nature Clinical Practice Rheumatology, 2009, 5, 18-19.	3.2	18
221	Long-Acting Î²2Agonists and Inhaled Corticosteroids in Asthma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 853-854.	5.6	0
222	Effect of levocetirizine on nasal provocation testing with adenosine monophosphate compared with allergen challenge in allergic rhinitis. Clinical and Experimental Allergy, 2009, 39, 409-416.	2.9	8
223	In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three antiâ€static spacers and a metered dose inhaler. British Journal of Clinical Pharmacology, 2009, 67, 191-198.	2.4	22
224	A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Pulmonary Pharmacology and Therapeutics, 2009, 22, 305-310.	2.6	17
225	Levalbuterol kinetics. Journal of Allergy and Clinical Immunology, 2009, 123, 275.	2.9	0
226	Adrenergic Î²2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. Journal of Allergy and Clinical Immunology, 2009, 124, 1188-1194.e3.	2.9	96
227	Î² blockers for asthma: a double-edged sword. Lancet, The, 2009, 373, 104-105.	13.7	27
228	A proof-of-concept study to evaluate the anti-inflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Annals of Allergy, Asthma and Immunology, 2009, 102, 161-167.	1.0	8
229	Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children. Annals of Allergy, Asthma and Immunology, 2009, 103, 436-441.	1.0	14
230	Comparative safety and efficacy of 2 formulations of fluticasone aqueous nasal spray in persistent allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2009, 102, 76-83.	1.0	9
231	Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1211-1217.	5.7	46
232	Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler. British Journal of Clinical Pharmacology, 2008, 66, 20-26.	2.4	20
233	Symptoms, spirometry, exhaled nitric oxide, and asthma exacerbations in clinical practice. Annals of Allergy, Asthma and Immunology, 2008, 101, 248-255.	1.0	19
234	Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat Exposure. PLoS Medicine, 2008, 5, e131.	8.4	215

#	Article	IF	Citations
235	Portable Exhaled Nitric Oxide Measurement. Chest, 2007, 131, 410-414.	0.8	155
236	Respiratory Symptoms and Inflammation After a Smoking Banâ€"Reply. JAMA - Journal of the American Medical Association, 2007, 297, 359.	7.4	0
237	A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respiratory Medicine, 2007, 101, 1218-1228.	2.9	78
238	Long-acting Î²2-adrenoceptor agonists: a smart choice for asthma?. Trends in Pharmacological Sciences, 2007, 28, 257-262.	8.7	28
239	Removing nasal valve obstruction in peak nasal inspiratory flow measurement. Annals of Allergy, Asthma and Immunology, 2007, 99, 59-60.	1.0	13
240	An in vivo and in vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber. Annals of Allergy, Asthma and Immunology, 2007, 98, 471-479.	1.0	7
241	Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 328-335.	2.9	114
242	Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 73-80.	5.7	29
243	Differential anti-inflammatory effects of large and small particle size inhaled corticosteroids in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 661-667.	5.7	21
244	Comment on: ?Obtaining concomitant control of allergic rhinitis and asthma with intranasal corticosteroid?. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1214-1214.	5.7	2
245	A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. Clinical and Experimental Allergy, 2007, 37, 696-703.	2.9	12
246	Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology, 2007, 64, 698-705.	2.4	17
247	Non-Invasive Measurement of Airway Inflammation in Asthma. Journal of Asthma, 2006, 43, 407-415.	1.7	20
248	Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?. Annals of Allergy, Asthma and Immunology, 2006, 96, 640-642.	1.0	5
249	A comparison of 2 extrafine hydrofluoroalkane-134aâ€"beclomethasone formulations on methacholine hyperresponsiveness. Annals of Allergy, Asthma and Immunology, 2006, 96, 422-430.	1.0	28
250	Long-Acting ??2-Agonists in Asthma. Drug Safety, 2006, 29, 647-656.	3.2	24
251	Evaluating the Effects of â€œTriple Therapyâ€•With Inhaled Corticosteroids, Long-Acting Î² 2 -Agonists, and Leukotriene Modifiers in Asthma. Chest, 2006, 130, 301-302.	0.8	2
252	The effect of beta2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 254-259.	5.7	13

#	Article	IF	Citations
253	Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1319-1325.	5.7	15
254	Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2006, 36, 676-684.	2.9	72
255	Pharmacological managementâ€"oral treatment. BMJ: British Medical Journal, 2006, 332, 1497-1499.	2.3	3
256	Respiratory Symptoms, Pulmonary Function, and Markers of Inflammation Among Bar Workers Before and After a Legislative Ban on Smoking in Public Places. JAMA - Journal of the American Medical Association, 2006, 296, 1742.	7.4	225
257	Arginine-16 Â2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax, 2006, 61, 940-944.	5.6	142
258	Clinical importance of the Step 3 choice in asthma. Thorax, 2006, 61, 180-1; author reply 181.	5.6	3
259	Airway and Systemic Effects of Hydrofluoroalkane Formulations of High-Dose Ciclesonide and Fluticasone in Moderate Persistent Asthma. Chest, 2005, 127, 851-860.	0.8	75
260	Evaluation of an Abbreviated Adenosine Monophosphate Bronchial Challenge. Chest, 2005, 127, 2222-2225.	0.8	6
261	Dose-response to salbutamol via a novel palm sized nebuliser (AerodoseR Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolintm Evohalertm) in moderate to severe asthmatics. British Journal of Clinical Pharmacology, 2005, 59, 5-13.	2.4	15
262	Pharmacological interventions and outcome measurements in the unified airway. Clinical and Experimental Allergy Reviews, 2005, 5, 26-31.	0.3	1
263	H1-Antihistamines. New England Journal of Medicine, 2005, 352, 1155-1157.	27.0	0
264	An Own GOAL or a Real Breakthrough?. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1060-1060.	5.6	2
265	Designer Inhaled Corticosteroids. Chest, 2005, 128, 1081-1084.	0.8	4
266	Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, The, 2005, 365, 167-175.	13.7	376
267	Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Annals of Allergy, Asthma and Immunology, 2005, 94, 465-472.	1.0	121
268	Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Annals of Allergy, Asthma and Immunology, 2005, 94, 675-681.	1.0	14
269	COMBINATION THERAPY WITH A LONG-ACTING Î²2-AGONIST AND AN INHALED CORTICOSTEROID AS INITIAL MAINTENANCE TREATMENT IN ASTHMA. Annals of Allergy, Asthma and Immunology, 2005, 94, 410-411.	1.0	1
270	Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Annals of Allergy, Asthma and Immunology, 2005, 95, 283-290.	1.0	9

#	Article	IF	Citations
271	In vitro synergism of inhaled corticosteroid and long-acting Î²2-agonist is not translated clinically in vivo. Journal of Allergy and Clinical Immunology, 2005, 115, 880.	2.9	2
272	Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Annals of Allergy, Asthma and Immunology, 2005, 95, 259-265.	1.0	12
273	Cross tolerance to salbutamol occurs independently of Â2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax, 2004, 59, 662-667.	5.6	33
274	Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. European Respiratory Journal, 2004, 24, 226-230.	6.7	35
275	Repeated Dosing Effects of Mediator Antagonists in Inhaled Corticosteroid-Treated Atopic Asthmatic Patients. Chest, 2004, 125, 1372-1377.	0.8	18
276	Does Bronchial Hyperresponsiveness in Asthma Matter?. Journal of Asthma, 2004, 41, 247-258.	1.7	29
277	Lower thresholds for bronchial challenge testing. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1125-1126.	5.7	3
278	Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. British Journal of Clinical Pharmacology, 2004, 57, 714-719.	2.4	23
279	Effects of hydrofluoroalkane formulations of ciclesonide 400 ug once daily vs fluticasone 250 ug twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. British Journal of Clinical Pharmacology, 2004, 58, 26-33.	2.4	46
280	Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. British Journal of Clinical Pharmacology, 2004, 58, 34-39.	2.4	28
281	Intranasal and inhaled corticosteroids in allergic rhinitis and asthma. British Journal of Clinical Pharmacology, 2004, 58, 447-448.	2.4	3
282	Butterbur, a herbal remedy, confers complementary anti-inflammatory activity in asthmatic patients receiving inhaled corticosteroids. Clinical and Experimental Allergy, 2004, 34, 110-114.	2.9	26
283	A placeboâ€controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clinical and Experimental Allergy, 2004, 34, 646-649.	2.9	43
284	Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clinical and Experimental Allergy, 2004, 34, 650-653.	2.9	44
285	Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype. European Journal of Clinical Pharmacology, 2004, 59, 791-795.	1.9	7
286	Combined mediator antagonism for allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 276-279.	5.7	5
287	The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology, 2004, 57, 388-392.	2.4	11
288	Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. Annals of Allergy, Asthma and Immunology, 2004, 93, 365-372.	1.0	18

#	Article	IF	Citations
289	Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. Annals of Allergy, Asthma and Immunology, 2004, 93, 56-60.	1.0	41
290	Reproducibility of response to nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Annals of Allergy, Asthma and Immunology, 2004, 93, 185-188.	1.0	21
291	Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 960-966.	5.6	83
292	Benefit-Risk Assessment of Long-Acting ??2-Agonists in Asthma. Drug Safety, 2004, 27, 243-270.	3.2	32
293	The effects of butterbur on the histamine and allergen cutaneous response. Annals of Allergy, Asthma and Immunology, 2004, 92, 250-254.	1.0	23
294	Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Annals of Allergy, Asthma and Immunology, 2004, 93, 253-258.	1.0	27
295	The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. European Journal of Clinical Pharmacology, 2003, 58, 643-647.	1.9	10
296	Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. European Journal of Clinical Pharmacology, 2003, 59, 11-15.	1.9	29
297	Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 602-607.	5.7	29
298	Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 762-766.	5.7	40
299	Relationship of skin-prick reactivity to aeroallergens and hyperresponsiveness to challenges with methacholine and adenosine monophosphate. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 46-52.	5.7	25
300	Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting. Allergology International, 2003, 52, 71-75.	3.3	0
301	Reproducibility of nasal function measurements with histamine and adenosine monophosphate nasal challenge testing in patients with allergic rhinitis. Allergology International, 2003, 52, 155-160.	3.3	3
302	Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clinical and Experimental Allergy, 2003, 33, 287-294.	2.9	23
303	Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. British Journal of Clinical Pharmacology, 2003, 55, 310-313.	2.4	19
304	An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. British Journal of Clinical Pharmacology, 2003, 55, 354-359.	2.4	14
305	The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. British Journal of Clinical Pharmacology, 2003, 55, 639-642.	2.4	13
306	A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. British Journal of Clinical Pharmacology, 2003, 55, 609-615.	2.4	13

#	Article	IF	Citations
307	Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. British Journal of Clinical Pharmacology, 2003, 56, 11-17.	2.4	55
308	Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology, 2003, 56, 494-500.	2.4	47
309	Add-on therapy with montelukast or formoterol in patients with the glycine-16 Î²2 -receptor genotype. British Journal of Clinical Pharmacology, 2003, 56, 104-111.	2.4	21
310	Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. British Journal of Clinical Pharmacology, 2003, 56, 422-426.	2.4	38
311	The arginine-16 Î²2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. British Journal of Clinical Pharmacology, 2003, 57, 68-75.	2.4	117
312	Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous Î²2-adrenoceptor haplotypes at positions 16 and 27. British Journal of Clinical Pharmacology, 2003, 57, 100-104.	2.4	20
313	Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clinical and Experimental Allergy, 2003, 33, 783-788.	2.9	53
314	Eosinophils from patients with asthma express higher levels of the pan-leucocyte receptor CD45 and the isoform CD45RO. Clinical and Experimental Allergy, 2003, 33, 936-941.	2.9	11
315	Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2003, 33, 882-886.	2.9	43
316	Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients. Clinical and Experimental Allergy, 2003, 33, 1405-1408.	2.9	21
317	Determinants of airway hyperresponsiveness in mild asthma. Annals of Allergy, Asthma and Immunology, 2003, 90, 560-563.	1.0	27
318	Effects of salmeterol on smooth muscle versus inflammatory outcomes. Journal of Allergy and Clinical Immunology, 2003, 112, 223.	2.9	1
319	Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. Journal of Allergy and Clinical Immunology, 2003, 111, 337-341.	2.9	28
320	Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Annals of Allergy, Asthma and Immunology, 2003, 90, 194-198.	1.0	62
321	Decongestant effects of antihistamines: A class effect?. Journal of Allergy and Clinical Immunology, 2003, 111, 653.	2.9	1
322	Asthma exacerbations and sputum eosinophil counts. Lancet, The, 2003, 361, 1302-1303.	13.7	4
323	LUNG BIOAVAILABILITY OF SPACERS. Annals of Allergy, Asthma and Immunology, 2003, 90, 674.	1.0	0
324	Relationship Between Changes in Quality of Life and Measures of Lung Function and Bronchial Hyper-Responsiveness During High-Dose Inhaled Corticosteroid Treatment in Uncontrolled Asthma. Treatments in Respiratory Medicine, 2003, 2, 433-438.	1.2	9

#	Article	IF	Citations
325	Effects of Montelukast on Surrogate Inflammatory Markers in Corticosteroid-treated Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1232-1238.	5.6	104
326	Airway-stabilizing effect of long-acting Â2-agonists as add-on therapy to inhaled corticosteroids. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 435-440.	0.5	25
327	Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology, 2003, 41, 16-20.	1.3	6
328	The GP's role in allergic rhinitis. Practitioner, 2003, 247, 418-23.	0.3	0
329	Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax, 2002, 57, 865-868.	5.6	15
330	Duration of Steroid Therapy Determines Dose-Response Effect. Chest, 2002, 121, 306-307.	0.8	0
331	Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate. Chest, 2002, 122, 618-623.	0.8	24
332	Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma. Chest, 2002, 122, 151-159.	0.8	40
333	Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol. Chest, 2002, 121, 1382.	0.8	1
334	Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma. Chest, 2002, 122, 146-150.	0.8	36
335	Sustained bronchoprotection with montelukast but not formoterol as add on therapy in asthmatics with the homozygous glycine 16 b2 adrenoceptor genotype. Journal of Allergy and Clinical Immunology, 2002, 109, S157-S157.	2.9	6
336	Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 68-74.	2.9	58
337	Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134aâ€"beclomethasone alone. Journal of Allergy and Clinical Immunology, 2002, 109, 929-935.	2.9	46
338	Second-Line Controller Therapy for Persistent Asthma Uncontrolled on Inhaled Corticosteroids. Drugs, 2002, 62, 2315-2332.	10.9	9
339	5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. European Journal of Clinical Pharmacology, 2002, 58, 187-190.	1.9	35
340	A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2002, 32, 126-132.	2.9	56
341	Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2002, 32, 1504-1509.	2.9	61
342	Antagonism of long-acting Î²2-adrenoceptor agonism. British Journal of Clinical Pharmacology, 2002, 54, 231-245.	2.4	17

#	Article	IF	Citations
343	Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. British Journal of Clinical Pharmacology, 2002, 54, 544-547.	2.4	16
344	Adrenal insufficiency after treatment with fluticasone. BMJ: British Medical Journal, 2002, 325, 836a-836.	2.3	4
345	BUDESONIDE DOSE-RESPONSE IN MILD PERSISTENT ASTHMA. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1188-1189.	5.6	3
346	THE STEP 3 DILEMMA FOR MODERATE PERSISTENT ASTHMA. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1022-1023.	5.6	0
347	Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology, 2002, 40, 66-8.	1.3	4
348	Fluticasone propionate/salmeterol combination. Journal of Allergy and Clinical Immunology, 2001, 107, 746.	2.9	2
349	Budesonide/Formoterol Combination. Drugs, 2001, 61, 79-80.	10.9	1
350	Letter to the Editor. Respiratory Medicine, 2001, 95, 160-161.	2.9	0
351	Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2001, 87, 344-349.	1.0	60
352	Adrenal suppression with inhaled corticosteroids. Annals of Allergy, Asthma and Immunology, 2001, 87, 359-361.	1.0	17
353	Fluticasone and Cortisol Measurements. Chest, 2001, 119, 984.	0.8	2
354	Lost in the Labyrinth of End Points. Chest, 2001, 120, 323-324.	0.8	4
355	Mometason Furoate Levels. Chest, 2001, 120, 1034-1035.	0.8	6
356	Optimizing Bronchodilator Therapy for COPD. Chest, 2001, 119, 1628-1630.	0.8	12
357	Pharmacokinetics and systemic Î²2 -adrenoceptor-mediated responses to inhaled salbutamol. British Journal of Clinical Pharmacology, 2001, 51, 359-362.	2.4	25
358	A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clinical and Experimental Allergy, 2001, 31, 616-624.	2.9	110
359	Emerging role of antileukotriene therapy in allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 1813-1821.	2.9	22
360	The role of long-acting Î²-agonists in patients uncontrolled on inhaled steroids alone - a pharmacological approach. Clinical and Experimental Allergy Reviews, 2001, 1, 23-28.	0.3	0

#	Article	IF	Citations
361	Systemic bioavailability of fluticasone proprionate. British Journal of Clinical Pharmacology, 2001, 52, 457-458.	2.4	1
362	Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal of Clinical Pharmacology, 2001, 52, 93-95.	2.4	25
363	Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. European Journal of Clinical Pharmacology, 2001, 57, 637-641.	1.9	8
364	Effects of monotherapy with intraâ€nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 61-68.	2.9	82
365	Comparative In Vivo Lung Delivery of Hydrofluoroalkane-Salbutamol Formulation Via Metered-Dose Inhaler Alone, With Plastic Spacer, or With Cardboard Tube. Chest, 2001, 119, 1018-1020.	0.8	9
366	Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids. Chest, 2001, 119, 1021-1026.	0.8	107
367	Revisiting interactions between hypoxaemia and beta2 agonists in asthma. Thorax, 2001, 56, 506-507.	5.6	11
368	COMPARABLE EFFICACY OF ADMINISTRATION WITH FACE MASK OR MOUTHPIECE OF NEBULIZED BUDESONIDE SUSPENSION FOR INFANTS AND YOUNG CHILDREN WITH PERSISTANT ASTHMA. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1277-1278.	5.6	0
369	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 61-68.	2.9	57
370	THE PROBLEM OF DOSE-RESPONSE AND THERAPEUTIC RATIO OF INHALED STEROIDS. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1758-1759.	5.6	2
371	Revisiting interactions between hypoxaemia and Î²2agonists in asthma. Thorax, 2001, 56, 506-507.	5.6	1
372	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2001, 31, 61-8.	2.9	30
373	Effects of Once-Daily Formoterol and Budesonide Given Alone or in Combination on Surrogate Inflammatory Markers in Asthmatic Adults. Chest, 2000, 118, 1049-1058.	0.8	70
374	Asthma and Cushing's Syndrome. Chest, 2000, 117, 593-594.	0.8	43
375	Functional Antagonism With Formoterol and Salmeterol in Asthmatic Patients Expressing the Homozygous Glycine-16 Î²2-Adrenoceptor Polymorphism. Chest, 2000, 118, 321-328.	0.8	48
376	Continuity of prescribing with inhaled corticosteroids and control of asthma. Pharmacoepidemiology and Drug Safety, 2000, 9, 293-303.	1.9	10
377	Influences on plasma cortisol of different formulations of beclomethasone dipropionate. British Journal of Clinical Pharmacology, 2000, 50, 381–381.	2.4	2
378	Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clinical and Experimental Allergy, 2000, 30, 833-838.	2.9	65

#	Article	IF	Citations
379	Allergic inflammation in the unified airway: start with the nose. Thorax, 2000, 55, 878-881.	5.6	43
380	Bronchodilator Response to Albuterol After Regular Formoterol and Effects of Acute Corticosteroid Administration. Chest, 2000, 117, 156-162.	0.8	108
381	Use of Fluticasone in Asthma. Chest, 2000, 117, 611-612.	0.8	1
382	Additive Bronchoprotective and Bronchodilator Effects With Single Doses of Salmeterol and Montelukast in Asthmatic Patients Receiving Inhaled Corticosteroids. Chest, 2000, 117, 950-953.	0.8	46
383	Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1297-1301.	5.6	82
384	Therapeutic ratio of inhaled fluticasone. Thorax, 2000, 55, 251a-251.	5.6	1
385	Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. American Journal of Medicine, 2000, 109, 114-121.	1.5	59
386	Doseâ€“response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. American Journal of Medicine, 2000, 108, 269-275.	1.5	125
387	Letters to the Editor. Respiratory Medicine, 2000, 94, 177.	2.9	10
388	Therapeutic implications of non-genomic glucocorticoid activity. Lancet, The, 2000, 356, 87-89.	13.7	96
389	Inhaled corticosteroids and bone density. Lancet, The, 2000, 356, 425.	13.7	1
390	Screening for Bronchial Hyperresponsiveness Using Methacholine and Adenosine Monophosphate. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1318-1322.	5.6	82
391	Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2000, 85, 111-114.	1.0	47
392	Safety of Inhaled and Intranasal Corticosteroids. Drug Safety, 2000, 23, 11-33.	3.2	189
393	Targets for inhaled treatment. Respiratory Medicine, 2000, 94, S13-S16.	2.9	12
394	The comparative safety/efficacy ratio of HFA-BDP. Respiratory Medicine, 2000, 94, S21-S26.	2.9	7
395	The ISOLDE trial. Side effects with inhaled steroids should not be forgotten. BMJ: British Medical Journal, 2000, 321, 1349.	2.3	3
396	Asthma management with HFA-BDP (Qvarâ„¢). British Journal of Hospital Medicine, 1999, 60, 263-270.	0.2	5

#	Article	IF	Citations
397	Effects of Genetic Polymorphism on Ex Vivo and In Vivo Function of Î²2-Adrenoceptors in Asthmatic Patients. Chest, 1999, 115, 324-328.	0.8	83
398	Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax, 1999, 54, 614-617.	5.6	20
399	24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax, 1999, 54, 20-26.	5.6	69
400	Systemic Adverse Effects of Inhaled Corticosteroid Therapy. Archives of Internal Medicine, 1999, 159, 941.	3.8	819
401	Shortâ€term doseâ€response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. British Journal of Clinical Pharmacology, 1999, 48, 579-585.	2.4	40
402	Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. British Journal of Clinical Pharmacology, 1999, 48, 866-868.	2.4	29
403	Effect of electrostatic charge in plastic spacers on the lung delivery of HFAâ€salbutamol in children. British Journal of Clinical Pharmacology, 1999, 47, 333-336.	2.4	57
404	Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology, 1999, 50, 329-335.	2.4	25
405	Comparative trough effects of formoterol and salmeterol on lymphocyte Î² 2 -adrenoceptor - regulation and bronchodilatation. European Journal of Clinical Pharmacology, 1999, 55, 431-436.	1.9	12
406	Leukotriene-receptor antagonists. Lancet, The, 1999, 353, 57-62.	13.7	212
407	Importance of drug-device interaction in determining systemic effects of inhaled cor ticosteroids. Lancet, The, 1999, 353, 2128.	13.7	37
408	Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet, The, 1999, 354, 1357-1358.	13.7	28
409	Effects of oral and inhaled corticosteroids on the hypothalamic-pituitary-adrenal axis. Journal of Allergy and Clinical Immunology, 1999, 104, 713.	2.9	9
410	In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol. Journal of Allergy and Clinical Immunology, 1999, 103, 816-822.	2.9	40
411	A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. Journal of Allergy and Clinical Immunology, 1999, 103, 88-92.	2.9	61
412	Evaluation of the Effect of a Large Volume Spacer on the Systemic Bioactivity of Fluticasone Propionate Metered-Dose Inhaler. Chest, 1999, 116, 935-940.	0.8	42
413	The Emerging Role of Leukotriene Antagonists in Asthma Therapy. Chest, 1999, 115, 313-316.	0.8	10
414	A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and Î²2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol. Chest, 1999, 115, 623-628.	0.8	71

#	Article	IF	Citations
415	Fortnightly review: Modern drug treatment of chronic asthma. BMJ: British Medical Journal, 1999, 318, 380-384.	2.3	38
416	Articles. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 2125-2126.	5.6	3
417	Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. Clinical Science, 1999, 96, 253-9.	4.3	21
418	Adrenocortical activity with repeated administration of one-daily inhaled fluticasone propionate and budesonide in asthmatic adults. European Journal of Clinical Pharmacology, 1998, 53, 317-320.	1.9	26
419	Concomitant inhaled corticosteroid resensitises cardiac Î² 2 -adrenoceptors in the presence of long-acting Î² 2 -agonist therapy. European Journal of Clinical Pharmacology, 1998, 54, 377-381.	1.9	30
420	Early lung absorption profile of nonâ€CFC salbutamol via small and large volume plastic spacer devices. British Journal of Clinical Pharmacology, 1998, 46, 45-48.	2.4	67
421	Lung delivery of nonâ€CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer. British Journal of Clinical Pharmacology, 1998, 45, 160-163.	2.4	24
422	Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. British Journal of Clinical Pharmacology, 1998, 46, 263-266.	2.4	12
423	Does use or withdrawal of long-acting Î²2-adrenoceptor induce desensitisation?. Lancet, The, 1998, 351, 67.	13.7	3
424	Fenoterol and asthma mortality. Lancet, The, 1998, 352, 486-487.	13.7	4
425	Effects of Treatment with Formoterol on Bronchoprotection against Methacholine. American Journal of Medicine, 1998, 104, 431-438.	1.5	101
426	Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adultsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 751-756.	2.9	21
427	Î²2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthmaâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 101, 337-341.	2.9	77
428	Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitisâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 598-604.	2.9	109
429	Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenalâ€“axis activity. Journal of Allergy and Clinical Immunology, 1998, 101, 470-474.	2.9	107
430	Dose Response to Inhaled Corticosteroids: Benefits and Risks. Seminars in Respiratory and Critical Care Medicine, 1998, 19, 625-646.	2.1	44
431	Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 922-925.	3.6	31
432	Systemic Bioactivity Profiles of Oral Prednisolone and Nebulized Budesonide in Adult Asthmatics. Chest, 1998, 114, 1022-1027.	0.8	37

#	Article	IF	Citations
433	Î²2-Adrenoceptor Regulation and Function in Female Asthmatic Patients Receiving the Oral Combined Contraceptive Pill. Chest, 1998, 113, 278-282.	0.8	13
434	Concomitant Administration of Low-Dose Prednisolone Protects Against In Vivo Î²2-Adrenoceptor Subsensitivity Induced by Regular Formoterol. Chest, 1998, 113, 34-41.	0.8	28
435	Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. European Respiratory Journal, 1998, 12, 580-584.	6.7	60
436	Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 922-925.	3.6	12
437	Systemic Corticosteriod Rapidly Reverses Bronchodilator Subsensitivity Induced by Formoterol in Asthmatic Patients. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 28-35.	5.6	146
438	Dose-response Effect for Adrenal Suppression with Repeated Twice Daily Inhaled Fluticasone Propionate and Triamcinolone Acetonide in Adult Asthmatics. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1274-1277.	5.6	45
439	Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.. Thorax, 1997, 52, 849-852.	5.6	50
440	Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax, 1997, 52, 55-58.	5.6	107
441	Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax, 1997, 52, 686-689.	5.6	50
442	Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax, 1997, 52, 608-611.	5.6	80
443	Use of Pulsed-Wave Doppler Echocardiography to Measure Changes in MPAP: To the Editor. Chest, 1997, 111, 1470.	0.8	2
444	Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax, 1997, 52, 1036-1039.	5.6	94
445	Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax, 1997, 52, 476-482.	5.6	132
446	Paradoxical Down-Regulation and Desensitization of Î²2-Adrenoceptors by Exogenous Progesterone in Female Asthmatics. Chest, 1997, 111, 847-851.	0.8	66
447	A Repeat Audit of Hospital Discharge Letters in Patients Admitted with Acute Asthma. Scottish Medical Journal, 1997, 42, 19-21.	1.3	7
448	Evaluation of Corticotropin Releasing Factor Stimulation and Basal Markers of Hypothalamic-Pituitary-Adrenal Axis Suppression in Asthmatic Patients. Chest, 1997, 112, 1248-1252.	0.8	28
449	Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 1273-1277.	5.6	100
450	Lung delivery of salbutamol by dry powder inhaler (TurbuhalerÂ®) and small volume antistatic metal spacer (AiromirÂ® CFC-free MDI plus NebuChamberÂ®). European Respiratory Journal, 1997, 10, 1820-1823.	6.7	17

#	Article	IF	Citations
451	Investigations on the renin-angiotensin system in acute severe asthma. European Respiratory Journal, 1997, 10, 2766-2771.	6.7	35
452	Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovascular Research, 1997, 33, 201-208.	3.8	65
453	Reaudit of Acute Asthma Admissions Using a Severity Marker Stamp and Determinants of an Outcome Measure. Scottish Medical Journal, 1997, 42, 49-52.	1.3	2
454	Dose-Response of Inhaled Drugs in Asthma. Clinical Pharmacokinetics, 1997, 32, 58-74.	3.5	49
455	Airway Subsensitivity with Long-Acting ??2-Agonists Is There Cause for Concern?. Drug Safety, 1997, 16, 295-308.	3.2	109
456	Lung Delivery of Salbutamol Given by Breath Activated Pressurized Aerosol and Dry Powder Inhaler Devices. Pulmonary Pharmacology and Therapeutics, 1997, 10, 211-214.	2.6	27
457	Association between Î²2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet, The, 1997, 350, 995-999.	13.7	347
458	Treatment of acute asthma. Lancet, The, 1997, 350, S18-S23.	13.7	50
459	Cardiopulmonary effects of endothelin-1 in man. Cardiovascular Research, 1997, 33, 378-386.	3.8	54
460	Effect of exogenous female sex-steroid hormones on Î² 2 -adrenoceptors in healthy males. European Journal of Clinical Pharmacology, 1997, 52, 281-283.	1.9	5
461	Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. European Journal of Clinical Pharmacology, 1997, 53, 33-37.	1.9	23
462	Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. European Journal of Clinical Pharmacology, 1997, 53, 47-49.	1.9	23
463	Effects of frusemide and hypoxia on the pulmonary vascular bed in man. British Journal of Clinical Pharmacology, 1997, 43, 309-313.	2.4	19
464	Effects of oral and inhaled corticosteroid on lymphocyte Î² 2 -adrenoceptor function in asthmatic patients. British Journal of Clinical Pharmacology, 1997, 44, 565-568.	2.4	10
465	Evaluation of partial ?-adrenoceptor agonist activity. British Journal of Clinical Pharmacology, 1997, 43, 9-14.	2.4	29
466	Effects of Hypercapnia on Hemodynamic, Inotropic, Lusitropic, and Electrophysiologic Indices in Humans. Chest, 1996, 109, 1215-1221.	0.8	188
467	Lisinopril Attenuates Acute Hypoxic Pulmonary Vasoconstriction in Humans. Chest, 1996, 109, 424-429.	0.8	58
468	Angiotensin 11 Receptor Blockade and Effects on Pulmonary Hemodynamics and Hypoxic Pulmonary Vasoconstriction in Humans. Chest, 1996, 110, 698-703.	0.8	37

#	Article	IF	Citations
469	Effects of Inhaled Fluticasone Propionate and Oral Prednisolone on Lymphocyte Î²2-Adrenoceptor Function in Asthmatic Patients. Chest, 1996, 109, 343-347.	0.8	28
470	Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Cor Pulmonale. Chest, 1996, 110, 1220-1225.	0.8	53
471	Acute neurohormonal responses to hypoxaemia in man. European Journal of Applied Physiology and Occupational Physiology, 1996, 72, 256-260.	1.2	16
472	Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism. European Journal of Clinical Pharmacology, 1996, 50, 275-277.	1.9	11
473	Evaluation of plasma and urinary salbutamol levels in COPD. European Journal of Clinical Pharmacology, 1996, 51, 91-93.	1.9	8
474	Airway and Systemic Effects of Inhaled Corticosteroids in Asthma: Dose Response Relationship. Pulmonary Pharmacology, 1996, 9, 19-27.	0.6	82
475	Pharmacokinetics of inhaled drugs. British Journal of Clinical Pharmacology, 1996, 42, 697-705.	2.4	165
476	Clinical pharmacology of Î²3 -adrenoceptors. British Journal of Clinical Pharmacology, 1996, 42, 291-300.	2.4	70
477	Effects of exogenous female sexâ€steroid hormones on lymphocyte Î² 2 â€adrenoceptors in normal females. British Journal of Clinical Pharmacology, 1996, 41, 414-416.	2.4	39
478	Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. British Journal of Clinical Pharmacology, 1996, 41, 247-249.	2.4	43
479	Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.. Thorax, 1996, 51, 54-58.	5.6	25
480	Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.. Thorax, 1996, 51, 981-984.	5.6	73
481	Lung bioavailability of generic and innovator salbutamol metered dose inhalers.. Thorax, 1996, 51, 325-326.	5.6	25
482	Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.. Thorax, 1996, 51, 585-589.	5.6	19
483	Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.. Thorax, 1996, 51, 689-693.	5.6	73
484	Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.. Thorax, 1996, 51, 262-266.	5.6	137
485	Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children.. Thorax, 1996, 51, 941-943.	5.6	55
486	Salmeterol in smokers with COPD.. Thorax, 1996, 51, 110-110.	5.6	0

#	Article	IF	Citations
487	Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the community. British Journal of General Practice, 1996, 46, 423-5.	1.4	7
488	C-Reactive Protein in Simple Community-Acquired Pneumonia. Chest, 1995, 107, 1028-1031.	0.8	90
489	C-Reactive Protein. Chest, 1995, 108, 1288-1291.	0.8	154
490	Adverse Effects of Hypoxaemia on Diastolic Filling in Humans. Clinical Science, 1995, 89, 165-169.	4.3	62
491	Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol.. Thorax, 1995, 50, 1062-1066.	5.6	44
492	Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. European Journal of Clinical Pharmacology, 1995, 49, 15-9.	1.9	14
493	A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. European Journal of Clinical Pharmacology, 1995, 48, 13-8.	1.9	5
494	Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.. Thorax, 1995, 50, 54-61.	5.6	41
495	Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone.. Thorax, 1995, 50, 134-138.	5.6	21
496	Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans.. Thorax, 1995, 50, 183-185.	5.6	32
497	Left Ventricular Systolic Performance During Acute Hypoxemia. Chest, 1995, 108, 899-902.	0.8	24
498	Hypoxaemia and release of endothelin-1.. Thorax, 1995, 50, 1308-1310.	5.6	37
499	Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.. Thorax, 1995, 50, 497-504.	5.6	122
500	Tolerance with beta 2â€adrenoceptor agonists: time for reappraisal.. British Journal of Clinical Pharmacology, 1995, 39, 109-118.	2.4	30
501	The role of the reninâ€angiotensin and natriuretic peptide systems in the pulmonary vasculature.. British Journal of Clinical Pharmacology, 1995, 40, 11-18.	2.4	31
502	Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers.. British Journal of Clinical Pharmacology, 1995, 40, 313-318.	2.4	7
503	Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.. British Journal of Clinical Pharmacology, 1995, 40, 585-590.	2.4	38
504	Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet, The, 1995, 346, 201-206.	13.7	187

#	Article	IF	Citations
505	New perspectives on inhaled drug delivery and systemic bioactivity.. Thorax, 1995, 50, 105-110.	5.6	119
506	Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. Cardiovascular Research, 1995, 29, 108-11.	3.8	17
507	Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Cardiovascular Research, 1995, 30, 875-80.	3.8	15
508	Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").. Thorax, 1994, 49, 762-770.	5.6	77
509	Bioavailability of salbutamol.. Thorax, 1994, 49, 1183-1183.	5.6	0
510	C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure.. Thorax, 1994, 49, 1247-1249.	5.6	45
511	Extrapulmonary ?2-responses to intravenous salbutamol during the menstrual cycle. European Journal of Clinical Pharmacology, 1994, 46, 511-5.	1.9	6
512	Hypoxaemia and the Renin-Angiotensin System: New Answers for Old Questions. Pulmonary Pharmacology, 1994, 7, 279-284.	0.6	1
513	Acute Effects of Hypoxaemia and Angiotensin II in the Human Pulmonary Vascular Bed. Pulmonary Pharmacology, 1994, 7, 305-310.	0.6	12
514	Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. American Heart Journal, 1994, 127, 1635-1636.	2.7	112
515	Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. American Journal of Medicine, 1994, 97, 29-37.	1.5	107
516	Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow.. British Journal of Clinical Pharmacology, 1994, 37, 273-278.	2.4	11
517	Cardiac effects of the beta 3â€adrenoceptor agonist BRL35135 in man.. British Journal of Clinical Pharmacology, 1994, 37, 363-369.	2.4	40
518	Influence of sexâ€steroid hormones on the regulation of lymphocyte beta 2â€adrenoceptors during the menstrual cycle.. British Journal of Clinical Pharmacology, 1994, 37, 583-588.	2.4	69
519	The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2â€adrenoceptor blockade.. British Journal of Clinical Pharmacology, 1994, 38, 103-108.	2.4	9
520	The effects of angiotensin II on circulating levels of natriuretic peptides.. British Journal of Clinical Pharmacology, 1994, 38, 139-142.	2.4	29
521	A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects [see comments]. British Journal of Clinical Pharmacology, 1994, 38, 527-532.	2.4	61
522	Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine, 1994, 88, 363-368.	2.9	258

#	Article	IF	Citations
523	Vasoconstrictor Effects of Angiotensin II on the Pulmonary Vascular Bed. Chest, 1994, 105, 1360-1364.	0.8	46
524	Asthma control. Lancet, The, 1994, 344, 760.	13.7	2
525	Comparison of parameters of in vitro lymphocyte ?2-adrenoceptor function in normal and asthmatic subjects. European Journal of Clinical Pharmacology, 1993, 45, 535-538.	1.9	13
526	Comparison of the extrapulmonary Î²₂â€adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered doseâ€inhaler and modified actuator device. British Journal of Clinical Pharmacology, 1993, 36, 445-450.	2.4	45
527	Î²â€adrenoceptor subtypes mediating the airways response to BRL 35135 in man. British Journal of Clinical Pharmacology, 1993, 36, 567-571.	2.4	3
528	Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects.. Thorax, 1993, 48, 656-658.	5.6	36
529	Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.. Thorax, 1993, 48, 1151-1155.	5.6	16
530	An Audit of Hospital Discharge Letters in Patients Admitted with Acute Asthma. Scottish Medical Journal, 1993, 38, 116-119.	1.3	9
531	Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline.. Thorax, 1992, 47, 1056-1059.	5.6	16
532	The Effects of Enalapril and Spironolactone on Terbutaline-Induced Hypokalemia. Chest, 1992, 102, 91-95.	0.8	3
533	Risks Versus Benefits of Inhaled ??2-Agonists in the Management of Asthma. Drug Safety, 1992, 7, 54-70.	3.2	50
534	Inhaled beta 2â€adrenoceptor agonists in asthma: help or hindrance?. British Journal of Clinical Pharmacology, 1992, 33, 129-138.	2.4	43
535	Evaluation of in vivo partial beta 1/beta 2â€agonist activity: a doseâ€ranging study with carteolol.. British Journal of Clinical Pharmacology, 1992, 33, 411-416.	2.4	9
536	Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.. British Journal of Clinical Pharmacology, 1992, 34, 337-343.	2.4	27
537	The beta-agonist controversy: fact or fiction?. Clinical and Experimental Allergy, 1992, 22, 659-664.	2.9	6
538	An audit of acute asthma admissions to a respiratory unit. Health Bulletin, 1992, 50, 389-98.	0.1	6
539	The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline.. British Journal of Clinical Pharmacology, 1991, 32, 630-632.	2.4	9
540	The effects of time and dose on the relative beta 1â€and beta 2â€adrenoceptor antagonism of betaxolol and atenolol.. British Journal of Clinical Pharmacology, 1991, 31, 154-159.	2.4	12

#	Article	IF	Citations
541	The effect of pindolol on creatine kinase is not due to beta 2â€•adrenoceptor partial agonist activity [letter; comment]. British Journal of Clinical Pharmacology, 1991, 31, 723-724.	2.4	4
542	Clinical Pharmacokinetics of Drugs Administered Buccally and Sublingually. Clinical Pharmacokinetics, 1991, 21, 83-94.	3.5	32
543	MEASUREMENT OF NORMAL HUMAN AIRWAYS RESPONSE TO Î²-ADRENOCEPTOR STIMULATION USING A FORCED OSCILLATION TECHNIQUE. Journal of Clinical Pharmacy and Therapeutics, 1991, 16, 187-191.	1.5	2
544	Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. European Journal of Clinical Pharmacology, 1991, 40, 255-260.	1.9	20
545	The effects of chronic dosing on the ?1 and ?2-adrenoceptor antagonism of betaxolol and atenolol. European Journal of Clinical Pharmacology, 1991, 40, 467-471.	1.9	7
546	A dose-ranging study to evaluate the Î²1-adrenoceptor selectivity of bisoprolol. European Journal of Clinical Pharmacology, 1991, 40, 135-139.	1.9	25
547	Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. European Journal of Clinical Pharmacology, 1990, 38, 203-5.	1.9	20
548	Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. European Journal of Clinical Pharmacology, 1990, 39, 281-285.	1.9	3
549	Hypokalemic and ECG Sequelae of Combined Beta-Agonist/Diuretic Therapy. Chest, 1990, 98, 811-815.	0.8	22
550	Comparison of the Effects of Prolonged Treatment with Low and High Doses of Inhaled Terbutaline on Beta-Adrenoceptor Responsiveness in Patients with Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1990, 142, 338-342.	2.9	38
551	A doseâ€ranging study to evaluate the betaâ€adrenoceptor selectivity of single doses of betaxolol.. British Journal of Clinical Pharmacology, 1990, 30, 119-126.	2.4	9
552	Tachyphylaxis to Systemic But Not to Airway Responses during Prolonged Therapy with High Dose Inhaled Salbutamol in Asthmatics. The American Review of Respiratory Disease, 1989, 140, 586-592.	2.9	147
553	Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade. European Journal of Clinical Pharmacology, 1989, 37, 297-300.	1.9	46
554	Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. European Journal of Clinical Pharmacology, 1989, 36, 239-245.	1.9	77
555	The biochemical effects of high-dose inhaled salbutamol in patients with asthma. European Journal of Clinical Pharmacology, 1989, 36, 357-360.	1.9	17
556	Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. American Journal of Medicine, 1989, 86, 653-657.	1.5	46
557	Systemic betaâ€adrenoceptor responses to salbutamol given by meteredâ€dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects.. British Journal of Clinical Pharmacology, 1989, 27, 837-842.	2.4	28
558	Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2â€adrenoceptor blockade.. British Journal of Clinical Pharmacology, 1989, 28, 95-102.	2.4	57

#	Article	IF	Citations
559	Betaâ€adrenoceptor responses to inhaled salbutamol in the elderly.. British Journal of Clinical Pharmacology, 1989, 28, 725-729.	2.4	15
560	Development of persistent late onset asthma following treatment with captopril. European Respiratory Journal, 1989, 2, 586-8.	6.7	4
561	Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in Patients with asthma. European Journal of Clinical Pharmacology, 1989, 37, 567-571.	1.9	36
562	Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. European Journal of Clinical Pharmacology, 1989, 37, 49-52.	1.9	14
563	Problems with asthma following treatment of thyrotoxicosis. British Journal of Diseases of the Chest, 1988, 82, 310-314.	0.5	9
564	Betaâ€adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.. British Journal of Clinical Pharmacology, 1988, 26, 527-533.	2.4	50
565	A Case of Eosinophilic Pleural Effusion Complicating Multiple Myeloma. Scottish Medical Journal, 1988, 33, 278-278.	1.3	5
566	Late Relapse of Desquamative Interstitial Pneumonia. The American Review of Respiratory Disease, 1987, 136, 1253-1255.	2.9	22